25 May 2020: Articles
Difficult to Diagnose: An Unusual Cause of Cavitary Lung Lesion
Unknown etiology, Challenging differential diagnosis
Hallie E. Norman EF 1, Jonathan M. Davis ACDEF 2*, Dipen Kadaria ABCD 2DOI: 10.12659/AJCR.921274
Am J Case Rep 2020; 21:e921274
Abstract
BACKGROUND: Cavitary lung lesions are commonly identified on thoracic imaging, but typically require further workup for definitive diagnosis.
CASE REPORT: Here, we present the case of a 40-year-old Middle Eastern male who presented with an unusual cause of cavitary lung lesion with associated pleural mass and pleural thickening. He underwent bronchoscopic biopsy and computer tomography (CT)-guided core needle biopsy, both of which were non-diagnostic. Surgical biopsy subsequently revealed hyalinized necrotizing granulomatous tissue, consistent with histoplasmosis, and the patient was treated with itraconazole, which he responded well to.
CONCLUSIONS: This case demonstrates the importance of identifying unusual causes of cavitary lung lesions and emphasizes the role of using proper tissue sampling for diagnosis.
Keywords: Biopsy, Histoplasmosis, Lung Diseases, Fungal, Multiple Pulmonary Nodules, Antifungal Agents, Itraconazole, Lung Diseases, Tomography, X-Ray Computed
Background
Cavitary lung lesions are a common abnormality seen on adult chest imaging, which come with a broad differential [1]. Diagnostic probabilities are strongly influenced by clinical context, such as immune status, chronic illnesses, and timeline of the lesion [1]. Cavitary lung lesions most often fall into 1 of 2 categories: infection and malignancy. Other less common causes are autoimmune-related diseases. History and physical examination are the essential first step in narrowing the differential diagnosis, but more advanced imaging and a biopsy are typically necessary to yield a definitive diagnosis. The combination of imaging and the duration of symptoms can help narrow the differential diagnosis using an algorithmic approach [2]. An acute process is classified as symptoms of less than 12 weeks and would be consistent with bacterial, nocardial, fungal, necrotizing pneumonias, and septic emboli. Whereas a chronic process with symptoms greater than 12 weeks would be supportive of mycobacterial, fungal, viral, malignancy, or autoimmune disorders. Radiographic imaging is not highly specific. While imaging can suggest a diagnosis, clinical context is required to form an accurate diagnosis. Common infectious causes of cavitary lesions in adults include tuberculosis, bacterial pneumonia, and mycoses [3]. In the Ohio and Mississippi River Valleys,
Case Report
A 40-year-old Middle Eastern male with a past medical history significant only for chronic, heavy cigarette smoking presented with shortness of breath on exertion and general fatigue. He had only traveled to the Middle East and United States in the past. His last visit to the Middle East was 2 years prior to his presentation. His symptoms were initially treated with albuterol and antibiotics. Chest x-Ray (CXR) revealed a peripheral left upper lobe (LUL) lesion. Computed tomography (CT) thorax without contrast then revealed a 3.0×1.4 cm pleural mass of the LUL with associated pleural thickening and ground glass (Figures 1–3), a 2.2×2.0 cm left lower lobe cavitary lesion (Figure 4), and left hilar adenopathy. Given his travel history, he was ruled out for both tuberculosis and schistosomiasis. The patient underwent CT-guided core needle biopsy of the left upper lung, which revealed necrotic debris, but was negative for malignancy, fungus, or acid-fast bacteria (AFB). A subsequent bronchoscopy with transbronchial biopsy and bronchoalveolar lavage (BAL) of the LLL, as well as endobronchial ultrasound/transbronchial needle aspiration of station 10L (>2 cm) was also negative for malignancy, fungus, or granuloma. Follow up CT thorax revealed that the lesions had increased to 4.0×1.9 cm in the LUL, 2.9×1.3 cm in the LLL, and 2.0×3.2 cm on the left hilar node. Six months later, the lesions had further increased to 4.5×2.5 cm in the LUL and 5.1×2.5×4.3 cm in the LLL on non-contrast CT. Two repeated attempts at CT-guided biopsy were followed by a video assisted thoracoscopic surgery (VATS), which were again negative for malignancy, fungus, or granuloma. Six months follow-up non-contrast CT again revealed interval increase to 5.6×4.1×4.2 cm in the LUL and 6.2×3.1×3.3 cm in the LLL, and hilar lymphadenopathy. Cardiothoracic Surgery unit was then consulted, and a 1.7×2.2 cm VATS biopsy of the LLL lesion yielded a hyalinized, necrotizing granuloma consistent with histoplasmosis. The patient was started on itraconazole at that time, which he responded to well.
Discussion
We described a rare case of histoplasmosis in an endemic area presenting in a patient with no immunosuppression. He presented with vague pulmonary symptoms, such as fatigue and shortness of breath. Imaging revealed hilar lymphadenopathy and cavitary lung lesions, which prompted further workup and biopsies. However, consecutive biopsies were negative for malignancy, fungus, and bacteria. A needle core biopsy and bronchoscopy only revealed necrotic tissue. Inconclusive imaging and biopsies delayed the diagnosis of histoplasmosis 6 months in this patient, who continued to suffer symptoms and experience decreased quality of life. The diagnosis was able to be confirmed after surgical biopsy of the left lower lobe (LLL) cavity in which histopathology was consistent with histoplasmosis.
Histoplasmosis is classically considered an endemic illness associated with the Ohio and Mississippi River Valley areas in America, in which Memphis is located, and parts of Asia and Africa. Increasingly cases are being recognized outside of this class geographic distribution. Other areas, such as Brazil, Argentina, India, and South Africa, are at risk as well [8]. A case was reported of an immunocompetent patient from Greece, a non-endemic area, who developed chronic pulmonary histoplasmosis and the only risk factor in developing histoplasmosis was his visit to America many years ago [9]. Physicians working within the classic endemic areas are usually familiar with the presentation and approach to diagnosis of histoplasmosis, but the importance for all physicians to become familiar with recognizing this disease is being demonstrated with these new cases. With rising numbers of cases in non-endemic areas, histoplasmosis, it is important to recognize the clinical manifestations, diagnostic approach, and treatment strategies of this disease [10].
The diagnosis of histoplasmosis is multifactorial. Clinical presentation, radiologic manifestations, and patient history can indicate histoplasmosis; however, a definitive diagnosis requires culture, fungal stains, serologic test, and/or microscopic visualization [18]. Isolation of the organism in culture remains the gold standard for the diagnosis of histoplasmosis, but the incubation can range from days to weeks. This can result in a significant delay in diagnosis and treatment, which can even be fatal in severe cases. Fungal staining allows for more rapid results than culture, but it has a lower sensitivity [19]. Antigen detection is another laboratory method that provides rapid results, with high sensitivity when both urine and serum are tested [20]. However, in regions where histoplasmosis is endemic in the population, positive antigen tests are of limited utility as many individuals are asymptomatic carriers. Recently, polymerase chain reaction (PCR) methods have shown rapid and reliable detection of histoplasmosis, as well as differentiation from other mycoses. A study showed the sensitivity and specificity of PCR assay for histoplasmosis was 73% and 100%, respectively [21]. Compared to culture methods, PCR methods are easier and safer for laboratory personnel. Delay of diagnosis can lead to progression of disease, as can inappropriate treatment. If inflammatory causes are incorrectly suspected, corticosteroid use would likely lead to progression of histoplasmosis [22].
Conclusions
In conclusion, our case demonstrates the importance of sensitive and specific clinical tests in establishing histoplasmosis diagnosis. It is also important to consider histoplasmosis in immunocompetent patients whose presentation is compatible with the diagnosis. Further research on histoplasmosis has demonstrated how non-endemic areas can also be affected by this disease, leading us to reconsider the bias toward classic epidemiologic distribution of histoplasmosis. Diagnosis of histoplasmosis requires dynamic physician knowledge of clinical symptoms, patient history, geographic distribution, and radiological presentation. Our patient did not fall into the typical patient population and biopsies initially failed to rule in a diagnosis which delayed treatment in our patient. Despite aggressive sampling, his diagnosis remained elusive until adequate tissue was surgically sampled. Studies have demonstrated PCR assay utility in diagnosis by accurately reaching a diagnosis in a shorter amount of time [23]. In the future, advances in diagnostic testing may preclude the need for surgical biopsy for patients, such as was required in this case.
References:
1.. Ryu JH, Swensen SJ, Cystic and cavitary lung diseases: Focal and diffuse: Mayo Clin Proc, 2003; 78(6); 744-52, pmid: 12934786
2.. Gafoor K, Patel S, Girvin F, Cavitary lung diseases: A clinical-radiologic algorithmic approach: Chest, 2018; 153(6); 1443-65, pmid: 29518379
3.. Gadkowski LB, Stout JE, Cavitary pulmonary disease: Clin Microbiol Rev, 2008; 21(2); 305-33, pmid: 18400799
4.. Sarosi GA, Voth DW, Dahl BA, Disseminated histoplasmosis: Results of long-term follow-up. A center for disease control cooperative mycoses study: Ann Intern Med, 1971; 75(4); 511-16, pmid: 5094067
5.. Evrard S, Caprasse P, Gavage P, Disseminated histoplasmosis: Case report and review of the literature: Acta Clin Belg, 2018; 73(5); 356-63, pmid: 28954600
6.. Armstrong PA, Jackson BR, Haselow D, Multistate epidemiology of histoplasmosis, United States, 2011–2014: Emerg Infect Dis, 2018; 24(3); 425-31, pmid: 29460731
7.. Kauffman CA, Histoplasmosis: A clinical and laboratory update: Clin Microbiol Rev, 2007; 20(1); 115-32, pmid: 17223625
8.. Bahr NC, Antinori S, Wheat LJ, Sarosi GA, Histoplasmosis infections worldwide: Thinking outside of the Ohio River valley: Curr Trop Med Rep, 2015; 2(2); 70-80, pmid: 26279969
9.. Botsa E, Thanou I, Kabanarou S, Thanos L, Rare case of pulmonary histoplasmosis complicated with bronchocentric granulomatosis in a non-endemic area: Respir Med Case Rep, 2017; 22; 1-3, pmid: 28616380
10.. Wheat LJ, Histoplasmosis: A review for clinicians from non-endemic areas: Mycoses, 2006; 49(4); 274-82, pmid: 16784440
11.. Gurney JW, Conces DJ, Pulmonary histoplasmosis: Radiology, 1996; 199(2); 297-306, pmid: 8668768
12.. McAdams HP, Rosado-de-Christenson ML, Lesar M, Thoracic mycoses from endemic fungi: radiologic-pathologic correlation: Radiographics, 1995; 15(2); 255-70, pmid: 7761632
13.. Zhu C, Wang G, Chen Q, Pulmonary histoplasmosis in an immunocompetent patient: A case report and literature review: Exp Ther Med, 2016; 12(5); 3256-60, pmid: 27882146
14.. Garfoot AL, Zemska O, Rappleye CA: Infect Immun, 2014; 82(1); 393-404, pmid: 24191299
15.. Staffolani S, Buonfrate D, Angheben A, Acute histoplasmosis in immunocompetent travelers: a systematic review of literature: BMC Infect Dis, 2018; 18(1); 673, pmid: 30563472
16.. Cuellar-Rodriguez J, Avery RK, Lard M, Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area: Clin Infect Dis, 2009; 49(5); 710-16, pmid: 19635026
17.. Goodwin RA, Owens FT, Snell JD, Chronic pulmonary histoplasmosis: Medicine (Baltimore), 1976; 55(6); 413-52, pmid: 792626
18.. Kurowski R, Ostapchuk M, Overview of histoplasmosis: Am Fam Physician, 2002; 66(12); 2247-52, pmid: 12507161
19.. Gomez BL, Figueroa JI, Hamilton AJ, Development of a novel antigen detection test for histoplasmosis: J Clin Microbiol, 1997; 35(10); 2618-22, pmid: 9316918
20.. Wheat J, Histoplasmosis: Experience during outbreaks in Indianapolis and review of the literature: Medicine (Baltimore), 1997; 76(5); 339-54, pmid: 9352737
21.. Babady NE, Buckwalter SP, Hall L: J Clin Microbiol, 2011; 49(9); 3204-8, pmid: 21752970
22.. Gudala M, Hegde S: Med Mycol Open Access, 2015; 1; 1
23.. Koepsell SA, Hinrichs SH, Iwen PC, Applying a real-time PCR assay for Histoplasma capsulatum to clinically relevant formalin-fixed paraffin-embedded human tissue: J Clin Microbiol, 2012; 50(10); 3395-97, pmid: 22855519
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






